Revolution Medicines (RVMD) CDO Alan Sandler Exercises Options, Sells Shares

What Happened

• Alan B. Sandler, Chief Development Officer at Revolution Medicines, exercised options to acquire 6,000 shares at a strike price of $58.84 (cost ≈ $353,040) on 2026-09-29. On the same date he sold multiple blocks of common stock (open-market sales) totaling 6,309 shares at weighted-average prices between $200.41 and $204.83, yielding approximately $1,275,294 in gross proceeds.
• The Form 4 also reports a derivative disposition of 6,000 shares at $0.00 (listed separately). The sales were executed under a 10b5-1 trading plan adopted by Mr. Sandler on June 30, 2026.

Key Details

• Transaction date: 2026-09-29; filing date: 2026-10-01 (appears timely).
• Option exercise: 6,000 shares @ $58.84 = $353,040 (acquisition).
• Open-market sales: 2,200 @ $200.82; 1,609 @ $201.72; 1,000 @ $202.81; 1,199 @ $203.91; 301 @ $204.72 — total proceeds ≈ $1,275,294. Footnotes F2–F6 note these were executed in multiple trades and the reported prices are weighted averages within stated ranges.
• Derivative disposition: 6,000 shares @ $0.00 reported as disposed (may reflect shares used in settlement/withholding; filing shows it as a derivative disposition).
• Holdings note: filing references 52,350 restricted stock units (F7). The total beneficial ownership after these transactions is not specified in the excerpt provided.
• Vesting note (F8): the related option had a vesting schedule beginning 9/29/2025 (25% at one year, then monthly vesting over 4 years).

Context

• This pattern—exercising options and selling shares the same day—is commonly a way to monetize vested options and/or satisfy tax/option obligations. The presence of a 10b5-1 plan indicates the sales were pre-arranged under an automated trading plan adopted 6/30/2026. These are routine insider transactions; they are factual disclosures rather than statements of intent or company outlook.